To Schedule an Appointment
+30 210 7258982
+357 22 276959
What is HYPPP Therapy//
HYPPP® Therapy is the result of over 15 years of laboratory and clinical research in the field of biomedicine, carried out at leading European Universities, such as the University College London (UCL, UK) and the Technical University of Munich (TUM, Germany). The therapy is based on an innovative wound healing process that mimics the natural wound microenvironment outside the body, termed 'Extracorporeal Hypoxia Preconditioning'.
This breakthrough scientific research work was carried out by a multi-disciplinary team of doctors and scientists, including internationally renowned plastic-reconstructive surgeons and leading academics in the field of regenerative medicine. The findings of the studies have been published in high-impact international scientific journals, while the therapy has received multiple prizes for scientific innovation, including the German Biotechnology Prize in 2013 , the TUM IDEAward 2014 and the Sciense4Life Award in 2016, as well as EXIST clinical development funding by the German Federal Ministry for Economic Affairs and Climate Action.
How HYPPP Therapy Works //
While wounds normally heal within 4-5 days, certain pathologies (e.g. diabetes, arterial disease) may disturb the normal wound healing process, leading to prolonged healing and development of chronic wounds. In these wounds, skin cells no longer respond as effectively to hypoxia (low oxygen tension), which is the natural stimulus for angiogenesis (generation of new blood vessels), a key prerequisite for optimal tissue repair. HYPPP® Therapy utilizes an innovative process that mimics the natural wound microenvironment outside the body, termed 'Extracorporeal Hypoxia Preconditioning'. By re-creating the normal wound healing conditions outside the body, peripheral white blood cells respond by producing the complete set of regenerative growth factors that have the ability to promote angiogenesis and cellular proliferation into the wound area. These factors are then isolated and applied topically to the wound in order to induce complete tissue repair and regeneration. HYPPP therapy has been to be both clinically safe and effective in treating large, full-thickness wounds arising due to post-operative complications, diabetic ulcers, as well as vascular ulcers and burns.
The HYPPP Therapy Protocol involves 3 steps:
-
Sampling of a small volume of peripheral venous blood from the patient
-
Hypoxia Preconditioning of blood outside the body for 4 days
-
Collection of HYPPP protein factors and topical application to the clean wound via a hydrophilic ointment product (surgical wound debridement maybe required prior to initiation of treatment, as indicated by the treating physician)
Clinical data indicate that large (>10cm2) full thickness wounds (tissue damage extending from the epidermis down to the muscle fascia layer) heal completely within an average of 2 to 3 months from initiation of treatment (note that results may vary depending on patient pathology and lifestyle).
Blood sampling Hypoxia Preconditioning HYPPP Therapy
CONFERENCE PRESENTATIONS//
DRG Revenues and costs of multimorbid patients in the German DRG system - analysis of the surgical treatment of chronic wounds at a university clinic using the example of pressure ulcers
DGPRÄC, Hamburg, Sept 2019
The role of Fibrin in Wound Angiogenesis - not a simple haemostatic block
DGPRÄC, Kassel, Sept 2016
Hypoxia Preconditioned Plasma (HPP) and its Role in promoting Angiogenesis-supported Wound Regeneration
PSRC 60th Annual Meeting, Seattle, May 2015
Activation of Angiogenesis through Autologous Hypoxia Preconditioned Products (HYPPP)
DGPRÄC, Berlin , Oct 2015
Isolation of Angiogenic Factors from Human Peripheral Blood for the Development of a Bioactive Dressing (*Award of Best Scientific Work)
EURAPS Research Council 3rd Annual Meeting, Isle of Ischia, May 2014
Scientific Publications //
Ektoras Hadjipanayi, Philipp M, Jun J, Ulf D, Hans-Günther M, Arndt F S.
Organogenesis. 2023 Dec 31;19(1):2234517. doi: 10.1080/15476278.2023.2234517.
Jiang J, Kraneburg U, Dornseifer U, Schilling AF, Hadjipanayi E, Machens HG, Moog P. Biomedicines. 2022 Jan 14;10(1):176. doi: 10.3390/biomedicines10010176.
Hypoxia Preconditioned Serum (HPS) Promotes Proliferation and Chondrogenic Phenotype of Chondrocytes In Vitro.
Jiang J, Altammar J, Cong X, Ramsauer L, Steinbacher V, Dornseifer U, Schilling AF, Machens HG, Moog P.
Int J Mol Sci. 2023 Jun 21;24(13):10441. doi: 10.3390/ijms241310441.
Jiang J, Cong X, Alageel S, Dornseifer U, Schilling AF, Hadjipanayi E, Machens HG, Moog P.Int J Mol Sci. 2023 Jan 19;24(3):1961. doi: 10.3390/ijms24031961.
Hadjipanayi E, Moog P, Bekeran S, Kirchhoff K, Berezhnoi A, Aguirre J, Bauer AT, Kükrek H, Schmauss D, Hopfner U, Isenburg S, Ntziachristos V, Ninkovic M, Machens HG, Schilling AF, Dornseifer U.
J Funct Biomater. 2019 May 13;10(2):22. doi: 10.3390/jfb10020022.
Moog P, Hughes J, Jiang J, Röper L, Dornseifer U, Schilling AF, Machens HG, Hadjipanayi E.
Int J Mol Sci. 2023 Mar 13;24(6):5485. doi: 10.3390/ijms24065485.
Jiang J, Röper L, Alageel S, Dornseifer U, Schilling AF, Hadjipanayi E, Machens HG, Moog P.Biomedicines. 2022
Jiang J, Röper L, Fuchs F, Hanschen M, Failer S, Alageel S, Cong X, Dornseifer U, Schilling AF, Machens HG, Moog P.Int J Mol Sci. 2024 May 13;25(10):5315. doi: 10.3390/ijms25105315.
Moog P, Kirchhoff K, Bekeran S, Bauer AT, von Isenburg S, Dornseifer U, Machens HG, Schilling AF, Hadjipanayi E.
Biomedicines. 2020 Jan 16;8(1):16. doi: 10.3390/biomedicines8010016.
Use of Oral Anticoagulation and Diabetes Do Not Inhibit the Angiogenic Potential of Hypoxia Preconditioned Blood-Derived Secretomes.
Moog P, Jensch M, Hughes J, Salgin B, Dornseifer U, Machens HG, Schilling AF, Hadjipanayi E.
Biomedicines. 2020 Aug 11;8(8):283.
Effect of Hypoxia Preconditioned Secretomes on Lymphangiogenic and Angiogenic Sprouting: An in Vitro Analysis.
Moog P, Schams R, Schneidinger A, Schilling AF, Machens HG, Hadjipanayi E, Dornseifer U.
Biomedicines. 2020 Sep 20;8(9):365.
Hadjipanayi E, Kuhn PH, Moog P, Bauer AT, Kuekrek H, Mirzoyan L, Hummel A, Kirchhoff K, Salgin B, Isenburg S, Dornseifer U, Ninkovic M, Machens HG, Schilling AF.
PLoS One. 2015 Aug 28;10(8):e0135618. doi: 10.1371/journal.pone.0135618. eCollection 2015.
Regeneration through autologous hypoxia preconditioned plasma.
Hadjipanayi E, Schilling AF.
Organogenesis. 2014 Apr-Jun;10(2):164-9. doi: 10.4161/org.29208. Epub 2014 May 15.
Hadjipanayi E, Bauer AT, Moog P, Salgin B, Kuekrek H, Fersch B, Hopfner U, Meissner T, Schlüter A, Ninkovic M, Machens HG, Schilling AF.
J Control Release. 2013 Jul 10;169(1-2):91-102. doi: 10.1016/j.jconrel.2013.04.008. Epub 2013 Apr 19.
Hadjipanayi E, Cheema U, Hopfner U, Bauer A, Machens HG, Schilling AF.
J Control Release. 2012 Aug 10;161(3):852-60. doi: 10.1016/j.jconrel.2012.04.048. Epub 2012 May 22.
First implantable device for hypoxia-mediated angiogenic induction.
Hadjipanayi E, Cheema U, Mudera V, Deng D, Liu W, Brown RA.
J Control Release. 2011 Aug 10;153(3):217-24. doi: 10.1016/j.jconrel.2011.03.029. Epub 2011 Mar 31.
Controlling physiological angiogenesis by hypoxia-induced signaling.
Hadjipanayi E, Brown RA, Mudera V, Deng D, Liu W, Cheema U.
J Control Release. 2010 Sep 15;146(3):309-17. doi: 10.1016/j.jconrel.2010.05.037. Epub 2010 Jun 9.
Hypoxia-based strategies for angiogenic induction: the dawn of a new era for ischemia therapy and tissue regeneration.
Hadjipanayi E, Schilling AF.
Organogenesis. 2013 Oct 1;9(4):261-72
